Effective October 1, 2011, outpatient facilities can obtain reimbursement for the intraocular telescopic implant for covered procedures. Medicare has granted transitional pass-through payment status and established a billing code for the device. FDA has approved it for patients with end-stage age-related macular degeneration, central vision blindness, failure to respond to AMD medications, or in patients that have a form of the disease for which no treatment is available.